Analysis of Drug Export Administration System in America Based on Revision of the Drug Administration Law

Abstract

Abstract: Objective To provide references for improving Chinese drug export administration in the revision of Drug Administration Law. Methods Domestic and foreign articles and regulations were searched. American drug export administration and its advantages were analyzed. Results The American drug export administration is stratified and focuses on the drug flow in order to make export drugs be traceable. Conclusion We should refer to traceable drug exportation which is the administration idea of FDA, regulate labeling, application, registration and recordkeeping requirements of drug export, and standardize the order of drug export, comprehensively grasp the conditions of drug export.

Key words: American, drug export, administration, references

CLC Number:

YOU Xiao-min, ZONG Mao-mao, CHAI Qian-wen, YANG Yue. Analysis of Drug Export Administration System in America Based on Revision of the Drug Administration Law[J]. Chinese Journal of Pharmacovigilance, 2015, 12(7): 406-410.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2015/V12/I7/406

References

[1] 中国医药保健品进出口商会. 2014年我国医药外贸再创历史新高[EB/OL].(2015-2-2)[2015-5-20]. http://www.cccmhpie.org.cn/Pub/6309/122265.shtml.
[2] 中财网. 2014我国中药类产品进出口概况[EB/OL].(2015-4-24)[2015-5-20]. http://cfi.net.cn/p20150424000909.html.
[3] CFDA.关于印发《药品加工出口管理规定（试行）》的通知[EB/OL].（2003-07-29）[2015-06-07]. http://www.sda.gov.cn/WS01/CL0058/9342.html.
[4] Govind Persad. The Medical Cost Pandemic : Why Limiting Access to Cost-Effective Treatments Hurts the Global Poor[J]. Chicago Journal of International Law,2015,15（2）: 559-611.
[5] FDA.Federal Food ,Drug and Cosmetic Act （FD&C Act）. SUBCHA-PTER VIII- Imports and Exports§381. Imports and exports [EB/OL]. （2014-10-03）[2015-01-15].http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapVIII-sec381.pdf.
[6] FDA.Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 [EB/OL].（2007-07-23） [2015-01-18].http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125898.pdf.
[7] FDA. Federal Food ,Drug and Cosmetic Act （FD&C Act）. SUBCHA-PTER VIII- Imports and Exports§382. Exports of certain unappr-oved products [EB/OL]. （2014-10-03） [2015-01-15]. http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapVIII-sec382.pdf .
[8] FDA. Code of Federal Regulations. Title 21 FOOD AND DRUGS§1.101 Notification and recordkeeping[EB/OL].（2014-04-01） [2015-01-18].http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol1/pdf/CFR-2014-title21-vol1-part1.pdf.
[9] FDA. Code of Federal Regulations. Title 21 FOOD AND DRUGS §312.110 Import and export requirements[EB/OL]. （2014-04-01） [2015-01-18].http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5-sec312-110.pdf.

[1]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[2]	ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang. Detection and analysis of signals of adverse events induced by deferasirox based on FAERS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
[3]	WEN Hairuo, HUANG Qin, HAN Suqin, JIANG Hua, QIN Chao, SHI Haokun, ZHAO Tingting, GENG Xingchao, WANG Qi. Mutagenicity risk of N-nitrosobumetanil in SD rats [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 307-312.
[4]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
[5]	LIU Meiting, MENG Jing, TIAN Jingzhuo, ZHAO Yong, YI Yan, LI Chunying, LIU Chenyue, CUI Shuang, ZHANG Yushi, WANG Lianmei, LIANG Aihua. Effect of long-term oral administration of Asari Radix et Rhizoma decoction and its main aristolochic acid analogs to mice main organs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1087-1094.
[6]	YANG Minghan, QIAO Meiling, LUO Jiaoyang, YANG Meihua, SHENG Ping. Acute toxicity of anti-gastric cancer active ingredients of Ferula ferulaeoides [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 880-884.
[7]	SHEN Ningning, LIU Yufu, RU Yi, SHI Zhuo, YANG Chunqi, NI Zhexin, XIAO Chengrong, MA Zengchun, WANG Yuguang, GAO Yue. Antifatigue effect of ophiopogonin D on exhaustive swimming in mice [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 749-753.
[8]	WANG Rong, LIU Ziqun, WANG Nana, TAN Xiong, ZHANG Yixin, YANG Kuan, QIN Bei. Acute toxicity of proline Danshensu borneol ester in mice [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 754-757.
[9]	ZUO Zeping, TIAN Yingying, XU Yi, JIANG Kewu, YANG Shuo, YANG Hairun, ZHANG Zhicong, CAO Xinyao, WU Xiaoru, WANG Zhibin. Preclinical safety evaluation of Jinkui Shenqi pills [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 775-782.
[10]	ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin. Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
[11]	ZHU Lan, JIN Zhe, LIU Lihong, ZHONG Lumiao, LIUXiaojun. Risks of Kangfuxiaoyan suppository due to routes of administration [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 306-310.
[12]	ZHENG Chengcheng, WANG Huiping, XU Baihui, XU Jiaoyan, LI Beibei, ZHANG Xiaohong, ZHANG Wei, SUN Ying, WANG Enli. Toxicity of Jingfang granule extract on embryo-fetal developmental of rats [J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 493-497.
[13]	ZHENG Chengcheng, XU Baihui, XU Jiaoyan, WANG Huiping, LI Beibei, ZHANG Xiaohong, SUN Ying, YAO Jingchun, WANG Enli. Toxicity of Jingfang granule extract on perinatal rats [J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 498-504.
[14]	XU Baihui, WANG Enli, ZHENG Chengcheng, XU Jiaoyan, LI Beibei, ZHANG Xiaohong, ZHOU Zhongyi, WANG Yonggang, YAO Jingchun. Toxicity of Jingfang granule extractum by 90 days repeated ingastric administration in rats [J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 510-514.
[15]	SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu. Research and reflection on regulatory science developments of U.S. FDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.